Eansor Norman David
Form 4
May 11, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

OMB APPROVAL

OMB Number:	3235-0287
Expires:	January 31, 2005
Estimated average burden hours per response...	0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Eansor Norman David

(Last) (First) (Middle)

8100 SOUTHPARK WAY, A-8

(Street)

LITTLETON, CO 80120

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol
BIO-TECHNE Corp [TECH]

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2018

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
SVP - Novus Biologicals

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/04/2018		S		1,136	D	$ 145.1864	2,266	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Pri Deriv Secu (Instr
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Units	(1)							(2)	(2)	Common Stock	1,500	
Restricted Stock Units	(1)							(3)	(3)	Common Stock	2,287	
Restricted Stock Units	(1)							(4)	(4)	Common Stock	2,174	
Stock Option (Right to Buy)	$ 108.49							(5)	08/07/2022	Common Stock	12,500	
Stock Option (Right to Buy)	$ 108.49							(2)	08/07/2022	Common Stock	9,375	
Stock Option (Right to Buy)	$ 94.35							(6)	08/12/2021	Common Stock	15,000	
Stock Options (Right to buy)	$ 125.05							(4)	08/09/2024	Common Stock	11,982	
Stock Options (Right to buy)	$ 125.05							(7)	08/09/2024	Common Stock	15,976	
Stock Options (Right to buy)	$ 106.59							(8)	08/18/2023	Common Stock	18,819	

Stock Options (Right to buy)	$ 106.59		(3)	08/18/2023	Common Stock	14,114

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Eansor Norman David 8100 SOUTHPARK WAY, A-8 LITTLETON, CO 80120			SVP - Novus Biologicals	

Signatures

/s/ Brenda S. Furlow, attorney in fact for N. David Eansor pursuant to Power of Attorney previously filed	05/11/2018
**Signature of Reporting Person	Date

Explanation of Responses:

***** If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(2) Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(3) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(4) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(5) 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.

(6) 3,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.

(7) Vest 3,994 shares on each 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021

(8) Vests 4,705 shares on 8/18/17, 8/18/18, and 8/18/19 and 4,704 shares on 8/18/20.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.